Postnatal serum insulin-like growth factor i and retinopathy of prematurity

Jensen, Anne K.; Ying, Gui‐Shuang; Huang, Jiayan; Quinn, Graham E.; Binenbaum, Gil

doi:10.1016/j.jaapos.2015.07.017

Cited by 4 publications

(8 citation statements)

References 25 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We are grateful to Doctors Reddy, Patel, and Sinha for their kind comments and interest. 1 It is interesting that their UK study 2 and our Philadelphia study 3 demonstrated similar IGF-1 levels in premature infants, but these levels were different in magnitude from the Swedish cohort. 4 Perhaps this observation is due to the IGF-1 assay used in each study.…”

mentioning

confidence: 75%

“…4 Perhaps this observation is due to the IGF-1 assay used in each study. In both the UK and Philadelphia studies, an immunoenzymatic assay was used, 2,3 while in the Swedish study, a radioimmunoassay was used. 4…”

mentioning

confidence: 99%

“…With regards to the modifying effect of race on the association between low serum IGF-1 and ROP, the UK study and Philadelphia study differed, as the former found an effect of race, 2 and the Philadelphia study did not. 3 One explanation is that the racial categories used by investigators may be inconsistent and result in heterogeneous and overlapping groups. This may explain inconsistencies across studies with regards to the association between race and ROP in the past.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Reply

Jensen

Binenbaum

2017

Retina

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 75%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Reply

Jensen

Binenbaum

2017

Retina

Self Cite

View full text Add to dashboard Cite

“…IGF-1 is an anabolic hormone that promotes the development of many types of body tissues including the retinal vasculature. An association has been found between early postnatal decrease in IGF-1 levels and the development of retinopathy of prematurity [14].…”

Section: New Criteria Regarding Risk Factorsmentioning

confidence: 99%

Risk factors for retinopathy of prematurity: a current literature review

Modrzejewska¹,

Czyżewska²,

Bosy-Gąsior³

et al. 2022

View full text Add to dashboard Cite

Aim of the study:To present the primary and secondary risk factors for the development of retinopathy of prematurity (ROP), as reported in the literature to date. Material and methods: Analysis of scientific papers and articles available in the PubMed, Google Scholar and UpToDate databases devoted to the study of risk factors involved in the development of retinopathy in premature infants, with attention given to the WIN-ROP and G-ROP algorithms used in ophthalmic screening tests. Conclusions:The best documented risk factors with a direct impact on ROP include low birth weight and preterm birth, low IGF-1 level, chorioamnionitis, and neonatal sepsis, while factors with an indirect impact on the development of ROP comprise bronchopulmonary dysplasia, necrotizing enterocolitis, apnea of prematurity, and respiratory distress syndrome (RDS).

show abstract

“…After term birth, neonate serum levels of IGF-1 decrease; this change is exacerbated in the setting of preterm birth [63]. Further, premature infants who develop ROP have lower serum levels of IGF-1 at birth compared to age-matched infants without disease, suggesting that low IGF-1 is an independent risk factor for subsequent ROP disease [64][65][66][67]. However, post-natal growth rate proved to be a suitable proxy for IGF-1 levels, and has largely replaced IGF-1 for modeling ROP risk.…”

Section: Preventive Interventions Informed By Rop Molecular Pathogenementioning

confidence: 99%

Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions

Carroll

Owen

2020

Exploration of Medicine

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a blinding morbidity of preterm infants, which represents a significant clinical problem, accounting for up to 40% of all childhood blindness. ROP displays a range of severity, though even mild disease may result in life-long visual impairment. This is complicated by the fact that our current treatments have significant ocular and potentially systemic effects. Therefore, disease prevention is desperately needed to mitigate the life-long deleterious effects of ROP for preterm infants. Although ROP demonstrates a delayed onset of retinal disease following preterm birth, representing a potential window for prevention, we have been unable to sufficiently alter the natural disease course and meaningfully prevent ROP. Prevention therapeutics requires knowledge of early ROP molecular changes and risk, occurring prior to clinical retinal disease. While we still have an incomplete understanding of these disease mechanisms, emerging data integrating contributions of maternal/placental pathobiology with ROP are poised to inform novel approaches to prevention. Herein, we review the molecular basis for current prevention strategies and the clinical outcomes of these interventions. We also discuss how insights into early ROP pathophysiology may be gained by a better understanding of maternal and placental factors playing a role in preterm birth.

show abstract

Postnatal serum insulin-like growth factor i and retinopathy of prematurity

Cited by 4 publications

References 25 publications

Reply

Reply

Risk factors for retinopathy of prematurity: a current literature review

Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions

Contact Info

Product

Resources

About